AMAS Blood Test for Cancer

The AMAS Cancer test is an innovative test that is based on levels of a specific antibody, shown to be elevated in a wide range of cancer types. This makes it different from most cancer tests which generally measure levels of an antigen associated with a particular cancer type. Oncolab Inc., the developer of the AMAS test, currently processes test results using samples from blood drawn at independent labs around North America. We are committed to quality assurance and rapid customer feedback.

The AMAS test measures serum levels of AMA, an antibody found to be elevated in most patients with a wide range of active non-terminal malignancies.

AMA is the antibody to Malignin, a 10,000 Dalton polypeptide which has been found to be present in most malignant cells regardless of cell type or location. Unlike tests such as CEA , which measure less well-defined antigens whose serum levels tend to be inconstant but elevated late in the disease, the AMAS test measures a well-defined antibody whose serum levels rise early in the course of the disease. In some cases, the AMAS test has been positive (elevated) early , i.e. 1 to 19 months before clinical detection.

Data from independent studies support the fact that the AMA (Anti-Malignin Antibody) is elevated almost regardless of the site or cell type of the malignancy; that is, AMA is a general transformation antibody, not just for one particular kind of cancer.